薬用ビグアニドによる哺乳類呼吸器複合体I抑制の構造的基礎
Hannah R Bridges1, James N Blaza1,2, Zhan Yin1
1MRC Mitochondrial Biology Unit, University of Cambridge, The Keith Peters Building, Cambridge Biomedical Campus, Cambridge CB2 0XY, UK.
まとめ
ビグアニドは,糖尿病に対するメトホルミンのように,新しい相互作用を通して呼吸器複合体Iを阻害します. この研究は,新しいビグアニド薬の開発に役立つ特定の結合部位とメカニズムを明らかにしています.
科学分野:
- 生物化学
- 構造生物学
- 薬理学について
背景:
- 糖尿病治療に使用されるメトホルミンなどのビグアニドの分子機構は不明である.
- ビグアニドの作用を理解することは 薬の開発に不可欠です
研究 の 目的:
- 哺乳類呼吸器複合体Iのモデルビグアニドの抑制薬標的相互作用を解明する.
- ビグアニドの作用のための構造的基礎を提供し,合理的な薬剤設計を導く.
主な方法:
- 複雑な構造を視覚化するための冷凍電子顕微鏡 (冷凍-EM).
- 抑制効果を定量化するための酵素動力学
- 結合選択性を理解するために構造的および運動的データを統合する.
主要な成果:
- 呼吸器複合体Iのキノン結合チャネルで主要な抑制結合部位を特定した.
- 膜間部に追加結合部位を発見した
- 膜領域のキーヘリクスを 移動させる新しいカオトロプ的相互作用を明らかにした.
結論:
- この研究は,呼吸器複合体Iのビグアニド抑制の詳細な構造的理解を提供します.
- これらの発見は,改良された特性を持つ新しい薬用ビグアニドの合理的な設計を可能にします.
- 特定された結合部位と相互作用は,将来の薬物開発の目標を提供します.
関連する概念動画
The Electron Transport Chain
17.1K
The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
17.1K
Electron Transport Chain: Complex I and II
14.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.7K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
489
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
489
The Supercomplexes in the Crista Membrane
2.6K
The mitochondrial cristae membrane is the primary site for the oxidative phosphorylation (OXPHOS) process of energy conversion mediated through respiratory complexes I to V. These complexes have been widely studied for decades, and it has been proven that they form supramolecular structures called respiratory supercomplexes (SC). These higher-order complexes may be crucial in maintaining the biochemical structure and improving the physiological activity of the individual complexes while...
2.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones
253
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
253
Cholinergic Antagonists: Pharmacological Actions
1.2K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.2K


